Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

Brokerages predict that Harvard Bioscience, Inc. (NASDAQ:HBIO - Get Rating) will report sales of $30.95 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Harvard Bioscience's earnings. The lowest sales estimate is $30.10 million and the highest is $31.80 million. Harvard Bioscience posted sales of $29.20 million in the same quarter last year, which suggests a positive year over year growth rate of 6%. The company is expected to issue its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Harvard Bioscience will report full year sales of $130.60 million for the current fiscal year, with estimates ranging from $130.30 million to $130.90 million. For the next financial year, analysts anticipate that the business will post sales of $145.50 million, with estimates ranging from $144.00 million to $147.00 million. Zacks' sales averages are a mean average based on a survey of research analysts that follow Harvard Bioscience.

Harvard Bioscience (NASDAQ:HBIO - Get Rating) last announced its earnings results on Wednesday, May 4th. The medical instruments supplier reported $0.04 EPS for the quarter, missing analysts' consensus estimates of $0.05 by ($0.01). Harvard Bioscience had a negative net margin of 5.38% and a positive return on equity of 9.06%. During the same period last year, the firm posted $0.03 EPS.

These 4 unique sectors - destined to be the new dominating forces in the market - and emerging as the next winners are so powerful they could turn every $1,000 into $140,130 within the next 36 months alone. Claim your free report here, to see exactly what they are and why they could replace FAANG stocks for good.

A number of brokerages have commented on HBIO. StockNews.com started coverage on Harvard Bioscience in a research note on Thursday, March 31st. They issued a "hold" rating for the company. Zacks Investment Research upgraded shares of Harvard Bioscience from a "hold" rating to a "buy" rating and set a $4.25 price objective for the company in a report on Tuesday, May 17th.

In other Harvard Bioscience news, CEO James W. Green bought 10,000 shares of the business's stock in a transaction on Monday, May 9th. The stock was purchased at an average price of $3.40 per share, for a total transaction of $34,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,319,955 shares of the company's stock, valued at $7,887,847. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO James W. Green bought 30,000 shares of the stock in a transaction that occurred on Friday, May 6th. The stock was bought at an average cost of $3.78 per share, for a total transaction of $113,400.00. Following the completion of the purchase, the chief executive officer now directly owns 2,309,955 shares of the company's stock, valued at $8,731,629.90. The disclosure for this purchase can be found here. 6.20% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in HBIO. Marshall Wace LLP boosted its holdings in Harvard Bioscience by 594.9% in the first quarter. Marshall Wace LLP now owns 86,543 shares of the medical instruments supplier's stock worth $373,000 after acquiring an additional 74,089 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Harvard Bioscience during the 3rd quarter worth about $103,000. Deutsche Bank AG increased its holdings in Harvard Bioscience by 8.7% during the 3rd quarter. Deutsche Bank AG now owns 24,931 shares of the medical instruments supplier's stock worth $174,000 after purchasing an additional 1,992 shares during the period. Barclays PLC grew its stake in Harvard Bioscience by 209.6% during the 3rd quarter. Barclays PLC now owns 16,056 shares of the medical instruments supplier's stock worth $112,000 after buying an additional 10,870 shares during the last quarter. Finally, Citigroup Inc. lifted its holdings in shares of Harvard Bioscience by 146.3% in the 3rd quarter. Citigroup Inc. now owns 4,512 shares of the medical instruments supplier's stock valued at $31,000 after buying an additional 2,680 shares during the period. Institutional investors and hedge funds own 72.75% of the company's stock.

Shares of NASDAQ HBIO opened at $3.68 on Monday. Harvard Bioscience has a 1 year low of $3.36 and a 1 year high of $8.75. The firm has a market cap of $151.77 million, a price-to-earnings ratio of -23.00 and a beta of 1.84. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.13 and a current ratio of 2.18. The stock's 50-day simple moving average is $5.39 and its 200-day simple moving average is $6.08.

Harvard Bioscience Company Profile (Get Rating)

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.

Featured ArticlesGet a free copy of the StockNews.com research report on Harvard Bioscience (HBIO)MarketBeat: Week in Review 5/16 – 5/203 Retailers That Defied First Quarter Headwinds Will John Deere’s Earnings Help to Calm the Markets?Rapid7: Could Be Profitable in FY 2022 Despite Bear MarketLowe’s Companies Has Not Bottomed 

Get a free copy of the Zacks research report on Harvard Bioscience (HBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Before you consider Harvard Bioscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harvard Bioscience wasn't on the list.

While Harvard Bioscience currently has a "N/A" rating among analysts, top-rated analysts believe these five stocks are better buys.

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Each market day you'll get a one-minute market summary to help you invest wisely.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.